secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001559053-25-000042
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena Q3 net loss $36.5M, nine-month loss $222.5M on charges; pipeline advances
--------------------------------------------------------------------------------

- Net loss for Q3 2025 was $36.5M ($0.68/sh) vs $59.0M ($1.10/sh) in Q3 2024; nine-month loss $222.5M ($4.13/sh) vs $64.4M ($1.20/sh).
- Revenue fell to $2.4M in Q3 2025 from $1.0M in Q3 2024; nine-month revenue $9.7M vs $133.0M primarily from BMS collaboration.
- Cash and equivalents $331.7M; no debt. FY2025 guidance: net cash used $170-178M, year-end cash ~$298M midpoint.
- Roche to initiate Phase 3 PARAISO prasinezumab trial for Parkinson's by end 2025; Novo Nordisk started Phase 3 CLEOPATTRA for coramitug in ATTR-CM.
- EGM on Nov 19 to vote on share capital reduction to support potential 2026 share redemption program; up to $105M in clinical milestones by end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905325000042/0001559053-25-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905325000042/prta-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001559053-25-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer